Enanta Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US29251M1062

SecurityENTA / Enanta Pharmaceuticals, Inc.
InstitutionBlackRock, Inc.
Latest Disclosed Ownership1,673,483 shares
Ownership 7.80%
BlackRock, Inc. ownership in ENTA / Enanta Pharmaceuticals, Inc.

2025-04-17 - BlackRock, Inc. has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 1,673,483 shares of Enanta Pharmaceuticals, Inc. (US:ENTA). This represents 7.8 percent ownership of the company. In their previous filing dated 2024-01-24 , BlackRock, Inc. had reported owning 1,934,711 shares, indicating a decrease of -13.50 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2025-04-17 2025-04-17 13G/A 1,934,711 1,673,483 -13.50 7.80 -15.22
2024-01-24 2024-01-24 13G/A 1,978,011 1,934,711 -2.19 9.20 -2.13
2023-10-06 2023-10-06 13G/A 3,753,075 1,978,011 -47.30 9.40 -47.78
2023-01-31 2023-01-31 13G 3,471,415 3,753,075 8.11 18.00 5.26
2022-01-28 2022-01-28 13G/A 3,406,000 3,471,415 1.92 17.10 0.59
2021-01-25 2021-01-25 13G 2,823,568 3,406,000 20.63 17.00 18.88
2020-02-04 2020-02-04 13G/A 2,573,488 2,823,568 9.72 14.30 8.33
2019-01-28 2019-01-28 13G/A 2,343,593 2,573,488 9.81 13.20 7.32
2018-01-19 2018-01-19 13G/A 2,066,119 2,343,593 13.43 12.30 12.84
2017-01-12 2017-01-12 13G/A 1,976,163 2,066,119 4.55 10.90 4.81
2016-12-09 2016-12-09 13G/A 1,677,254 1,976,163 17.82 10.40 16.85
2016-01-28 2016-01-28 13G 1,677,254 8.90

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 3,103,768 27,486 0.89 39,201 -19.20 0.0001
2026-02-12 2025-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 3,076,282 1,243,302 67.83 48,513 121.11 0.0008
2025-11-12 2025-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 1,832,980 -13,925 -0.75 21,941 57.14 0.0004
2025-08-12 2025-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 1,846,905 -171,764 -8.51 13,963 25.30 0.0003
2025-05-02 2025-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 2,018,669 -20,973 -1.03 11,143 -4.98 0.0002
2025-02-07 2024-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 2,039,642 139,319 7.33 11,728 -40.43 0.0002
2024-11-13 2024-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 1,900,323 52,804 2.86 19,687 -17.84 0.0004
2024-08-13 2024-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 1,847,519 8,464 0.46 23,962 -25.37 0.0005
2024-05-10 2024-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 1,839,055 -95,656 -4.94 32,110 76.37 0.0007
2024-02-13 2023-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 1,934,711 -44,349 -2.24 18,206 -17.65 0.0005
2023-11-13 2023-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 1,979,060 -1,751,638 -46.95 22,106 -72.31 0.0006
2023-08-11 2023-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 3,730,698 -45,704 -1.21 79,837 -47.72 0.0022
2023-05-12 2023-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 3,776,402 22,278 0.59 152,718 -12.55 0.0045
2023-02-13 2022-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 3,754,124 132,329 3.65 174,642 -7.04 0.0055
2022-11-14 2022-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 3,621,795 103,059 2.93 187,864 12.95 0.0064
2022-08-12 2022-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 3,518,736 2,130 0.06 166,331 -33.55 0.0053
2022-05-12 2022-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 3,516,606 45,191 1.30 250,312 -3.57 0.0067
2022-02-10 2021-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 3,471,415 -123,638 -3.44 259,592 27.10 0.0066
2021-11-09 2021-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 3,595,053 -76,953 -2.10 204,237 26.38 0.0057
2021-08-11 2021-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 3,672,006 -57,565 -1.54 161,606 -12.14 0.0045
2021-05-07 2021-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 3,729,571 323,571 9.50 183,943 28.28 0.0054
2021-02-05 2020-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 3,406,000 190,493 5.92 143,393 -2.59 0.0046
2020-11-06 2020-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 3,215,507 185,216 6.11 147,206 -3.25 0.0054
2020-08-14 2020-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 3,030,291 198,393 7.01 152,150 4.47 0.0061
2020-05-01 2020-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 2,831,898 8,330 0.30 145,646 -16.51 0.0071
2020-02-13 2019-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 2,823,568 211,377 8.09 174,441 11.15 0.0067
2019-11-08 2019-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 2,612,191 19,834 0.77 156,941 -28.25 0.0066
2019-08-22 2019-06-30 13F/A-1 ENANTA PHARMACEUTICALS COM 29251M106 2,592,357 37,417 1.46 218,743 -10.37 0.0094
2019-08-13 2019-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 2,592,357 37,417 218,743
2019-05-09 2019-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 2,554,940 -18,548 -0.72 244,047 33.89 0.0109
2019-02-08 2018-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 2,573,488 -16,678 -0.64 182,278 -17.65 0.0092
2018-11-09 2018-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 2,590,166 157,166 6.46 221,354 -21.50 0.0096
2018-08-09 2018-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 2,433,000 68,564 2.90 281,985 47.40 0.0130
2018-05-09 2018-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 2,364,436 20,843 0.89 191,308 39.11 0.0091
2018-02-09 2017-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 2,343,593 97,054 4.32 137,521 30.80 0.0065
2017-11-14 2017-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 2,246,539 48,342 2.20 105,138 32.93 0.0053
2017-08-10 2017-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 2,198,197 -96,690 -4.21 79,092 11.90 0.0042
2017-05-12 2017-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 2,294,887 2,286,323 26,696.91 70,682 24,527.87 0.0039
2017-02-10 2016-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 8,564 293 3.54 287 30.45 0.0004
2016-11-08 2016-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 8,271 3,657 79.26 220 115.69 0.0003
2016-08-10 2016-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 4,614 3,448 295.71 102 200.00 0.0002
2016-05-10 2016-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 1,166 809 226.61 34 183.33 0.0001
2016-02-11 2015-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 357 0 0.00 12 -7.69 0.0000
2015-11-13 2015-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 357 0 0.00 13 -18.75 0.0000
2015-08-07 2015-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 357 123 52.56 16 128.57 0.0000
2015-05-13 2015-03-31 13F ENANTA PHARMACEUTICALS COM 29251M106 234 0 0.00 7 -41.67 0.0000
2015-02-09 2014-12-31 13F ENANTA PHARMACEUTICALS COM 29251M106 234 0 0.00 12 33.33 0.0000
2014-10-29 2014-09-30 13F ENANTA PHARMACEUTICALS COM 29251M106 234 0 0.00 9 -10.00 0.0000
2014-08-06 2014-06-30 13F ENANTA PHARMACEUTICALS COM 29251M106 234 234 10 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.